Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CAR-T in MM: KarMMa, CARTITUDE-1 and EVOLVE

Meletios Dimopoulos • 22 May 2020
ASCO 2020
Multiple Myeloma Ciltacabtagene autoleucel Idecabtagene vicleucel Orvacabtagene autoleucel
CARTITUDE-1 EVOLVE KarMMa

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, gives a round up of the data from three CAR-T studies: KarMMa (NCT03361748), CARTITUDE-1 (NCT03548207) and EVOLVE (NCT03430011). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

1:07
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
0:49
KdD vs Kd for R/R MM: renal subgroup analysis from CANDOR
Meletios Dimopoulos • 10 Dec 2023
1:19
Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
1:34
iNNOVATE study update: long-term PFS in WM
Meletios Dimopoulos • 5 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals